Jeeyun Lee
A5019406140- Gastric Cancer Management and Outcomes
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Gastrointestinal Tumor Research and Treatment
- Esophageal Cancer Research and Treatment
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Helicobacter pylori-related gastroenterology studies
- Genetic factors in colorectal cancer
- Metastasis and carcinoma case studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- HER2/EGFR in Cancer Research
- Pancreatic and Hepatic Oncology Research
- Cancer Cells and Metastasis
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Treatment and Pharmacology
- Sarcoma Diagnosis and Treatment
- Cancer, Lipids, and Metabolism
- Lung Cancer Research Studies
- Fibroblast Growth Factor Research
- Monoclonal and Polyclonal Antibodies Research
- Advanced Breast Cancer Therapies
- Radiomics and Machine Learning in Medical Imaging
- Melanoma and MAPK Pathways
- Peptidase Inhibition and Analysis
Samsung Medical Center
2016-2025
Sungkyunkwan University
2016-2025
ABL Bio (South Korea)
2023
Merck Serono (Switzerland)
2023
AstraZeneca (Brazil)
2023
National University Cancer Institute, Singapore
2023
National University of Singapore
2023
Seoul Medical Center
2019
Samsung (South Korea)
2013-2018
Ghent University Hospital
2018
Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate consisting of anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and cytotoxic topoisomerase I inhibitor. The drug may have efficacy in patients with HER2-positive advanced gastric cancer.In open-label, randomized, phase 2 trial, we evaluated trastuzumab as compared chemotherapy cancer. Patients centrally confirmed or gastroesophageal junction adenocarcinoma that had progressed...
<h3>Importance</h3> Safe and effective therapies for untreated, advanced gastric/gastroesophageal junction (G/GEJ) cancer remain an unmet need. <h3>Objective</h3> To evaluate the antitumor activity of pembrolizumab, pembrolizumab plus chemotherapy, or chemotherapy alone in patients with G/GEJ programmed cell death ligand 1 (PD-L1) combined positive score (CPS) greater. <h3>Design, Setting, Participants</h3> The phase 3 KEYNOTE-062 randomized, controlled, partially blinded interventional...
Purpose The ARTIST (Adjuvant Chemoradiation Therapy in Stomach Cancer) trial was the first study to our knowledge investigate role of postoperative chemoradiotherapy therapy patients with curatively resected gastric cancer D2 lymph node dissection. This designed compare treatment capecitabine plus cisplatin (XP) versus XP radiotherapy (XP/XRT/XP). Patients and Methods arm received six cycles (capecitabine 2,000 mg/m 2 per day on days 1 14 60 1, repeated every 3 weeks) chemotherapy. XP/XRT/XP...
Entrectinib, a potent oral inhibitor of the tyrosine kinases TRKA/B/C, ROS1, and ALK, was evaluated in two phase I studies patients with advanced or metastatic solid tumors, including active central nervous system (CNS) disease. Here, we summarize overall safety report antitumor activity entrectinib cohort tumors harboring NTRK1/2/3, ALK gene fusions, naïve to prior TKI treatment targeting specific gene, who were treated at doses that achieved therapeutic exposures consistent recommended II...
Next-generation sequencing of cell-free circulating solid tumor DNA addresses two challenges in contemporary cancer care. First this method massively parallel and deep enables assessment a comprehensive panel genomic targets from single sample, second, it obviates the need for repeat invasive tissue biopsies. Digital SequencingTM is novel high-quality simultaneously across over 50 cancer-related genes with simple blood test. Here we report analytic clinical validation gene panel. Analytic...
When designing this trial, there was no evidence that salvage chemotherapy (SLC) in advanced gastric cancer (AGC) resulted substantial prolongation of survival when compared with best supportive care (BSC). However, SLC is often offered to pretreated patients AGC for anecdotal reasons.Patients one or two prior regimens involving both fluoropyrimidines and platinum an Eastern Cooperative Oncology Group performance status (PS) 0 1 were randomly assigned a ratio 2:1 plus BSC alone. Choice...
Purpose Patients with natural killer T (NK/T) -cell lymphomas have poor survival outcome, and for this condition there is no optimal therapy. The purpose of study was to design a prognostic model specifically extranodal NK/T-cell lymphoma, which can identify high-risk patients who need more aggressive Methods This multicenter retrospective comprised 262 were diagnosed lymphoma. Results After median follow-up duration 51.2 months, 5-year overall rate in 49.5%. Prognostic factors “B” symptoms...
The Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) trial tested whether the addition of radiotherapy to adjuvant chemotherapy improved disease-free survival (DFS) patients with D2-resected gastric cancer (GC).Between November 2004 and April 2008, 458 GC who received gastrectomy D2 lymph node dissection were randomly assigned either six cycles capecitabine cisplatin (XP) or two XP followed by chemoradiotherapy then additional (XPRT). This final update contains first publication overall...
The use of tyrosine kinase inhibitors (TKI) with activity against ALK, ROS1, or TRKA-C can result in significant clinical benefit patients diverse tumors harboring NTRK1-3 rearrangements; however, resistance invariably develops. emergence on-target domain mutations represents a major mechanism acquired resistance. Solvent-front substitutions such as ALKG1202R, ROS1G2032R ROS1D2033N, TRKAG595R, and TRKCG623R are among the most recalcitrant these mechanisms. Repotrectinib (TPX-0005) is...
Gastric cancer is a heterogeneous cancer, making treatment responses difficult to predict. Here we show that identify two distinct molecular subtypes, mesenchymal phenotype (MP) and epithelial (EP), by analyzing genomic proteomic data. Molecularly, MP subtype tumors high integrity characterized low mutation rates microsatellite stability, whereas EP integrity. Clinically, the associated with markedly poor survival resistance standard chemotherapy, better sensitivity chemotherapy. Integrative...
Immunotherapy has been associated with improved outcomes among patients who have received previous treatment for microsatellite instability-high (MSI-H) tumors.
ALK, ROS1, and NTRK fusions occur in 0.2% to 2.4% of colorectal cancers. Pioneer cases metastatic cancer (mCRC) patients bearing rearrangements who benefited from anti-ALK, ROS, TrkA-B-C therapies have been reported previously. Here we aimed at characterizing the clinical molecular landscape rearranged mCRC.Clinical features characteristics 27 mCRC tumors were compared with those a cohort 319 not by means Fisher's exact, χ2 test, or Mann-Whitney test as appropriate. Overall survival curves...
Abstract Gastroesophageal adenocarcinoma (GEA) is a lethal disease where targeted therapies, even when guided by genomic biomarkers, have had limited efficacy. A potential reason for the failure of such therapies that profiling results could commonly differ between primary and metastatic tumors. To evaluate heterogeneity, we sequenced paired GEA synchronous lesions across multiple cohorts, finding extensive differences in alterations, including discrepancies potentially clinically relevant...
<h3>Objective</h3> Differences in gastric cancer (GC) clinical outcomes between patients Asian and non-Asian countries has been historically attributed to variability management. However, recent international Phase III trials suggest that even with standardised treatments, GC differ by geography. Here, we investigated gene expression differences GCs, if these molecular might influence outcome. <h3>Design</h3> We compared profiles of 1016 GCs from six three cohorts, using a two-stage...
Solid tumors such as pancreatic ductal adenocarcinoma (PDAC) comprise not just tumor cells but also a microenvironment with which the constantly interact. Detailed characterization of cellular composition is critical to understanding disease and treatment patient. Single-cell transcriptomics has been used study different solid types including PDAC. However, almost all those studies primary tissues.In this study, we employed single-cell RNA sequencing technology profile transcriptomes...
Purpose We evaluated the activity of regorafenib, an oral multikinase inhibitor, in advanced gastric adenocarcinoma. Patients and Methods conducted international (Australia New Zealand, South Korea, Canada) randomized phase II trial which patients were randomly assigned at a two-to-one ratio stratified by lines prior chemotherapy for disease (one v two) region. Eligible received best supportive care plus regorafenib 160 mg or matching placebo orally on days 1 to 21 each 28-day cycle until...
Abstract The VIKTORY (targeted agent eValuation In gastric cancer basket KORea) trial was designed to classify patients with metastatic based on clinical sequencing and focused eight different biomarker groups (RAS aberration, TP53 mutation, PIK3CA mutation/amplification, MET amplification, overexpression, all negative, TSC2 deficient, or RICTOR amplification) assign one of the 10 associated trials in second-line (2L) treatment. Capivasertib (AKT inhibitor), savolitinib (MET selumetinib (MEK...
Abstract Purpose: Gastroesophageal adenocarcinoma (GEA) has a poor prognosis and few therapeutic options. Utilizing 73-gene plasma-based next-generation sequencing (NGS) cell-free circulating tumor DNA (ctDNA-NGS) test, we sought to evaluate the role of ctDNA-NGS in guiding clinical decision-making GEA. Experimental Design: We evaluated large cohort (n = 2,140 tests; 1,630 patients) results (including 369 clinically annotated patients). Patients were assessed for genomic alteration (GA)...